Pom/dex combinations as salvage for myeloma R/R to dara

DARA + pom-dex for R/R multiple myelomaПодробнее

Iberdomide in Combination with Dex and Dara, Bort, or Cfz in Pts with RRMMПодробнее

Carfilzomib 2x Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and DexПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

Pomalidomide + Low-Dose Dex + Dara in Relapsed and/or Refractory Multiple MyelomaПодробнее

Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myelomaПодробнее

The promise of pomalidomide-backbone combinations for R/R multiple myelomaПодробнее

ICARIA study: Isatuximab and pom/dex for multiple myelomaПодробнее

Elotuzumab with Car/Pom/Dex for high-risk R/R myelomaПодробнее

ASH 2018: Dara/Rev/Dex/Velcade for Newly Diagnosed Multiple Myeloma PatientsПодробнее

CyborD-DARA combination in first-line treatment for multiple myelomaПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

Update on iberdomide treatment combinations in R/R myelomaПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

R/R myeloma: iberdomide, dex & dara or bortezomibПодробнее

LIGHTHOUSE: A phase 3 study of melflufen in combination with dex and daratumumab vs dara in RRMM ptsПодробнее

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myelomaПодробнее

Daratumumab in combination with carfilzomib and dex in len-refractory patients with RMMПодробнее

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myelomaПодробнее